Kiniksa Pharmaceuticals International, plc KNSA Return on equity

Return on equity at other companies

Ligand PharmaceuticalsLGND

22%+16.9pp

Kymera TherapeuticsKYMR

-24.2%-5.2pp

Aurinia PharmaceuticalsAUPH

66.1%+48.8pp

Agios PharmaceuticalsAGIO

-34.3%—

Eton Pharmaceuticals, Inc.ETON

-34.2%+0.9pp

Opko HealthOPK

-5.9%-2.1pp

FAQ

What is Kiniksa Pharmaceuticals International, plc's return on equity?

Kiniksa Pharmaceuticals International, plc (KNSA) reported return on equity of 14% in Q2 2026.

How has Kiniksa Pharmaceuticals International, plc's return on equity changed year-over-year?

Kiniksa Pharmaceuticals International, plc's return on equity increased by 1262.9% year-over-year, from 1% to 14%.

What is the long-term trend for Kiniksa Pharmaceuticals International, plc's return on equity?

Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's return on equity has grown at a -27.9% compound annual growth rate (CAGR), from -60.1% to 11.7%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.